Use of fish oil to prevent graft rejection
نویسندگان
چکیده
منابع مشابه
Use of fish oil to prevent graft rejection.
Immunonutrition combining parenteral nutrition and pharmacological intervention has become of particular interest over the last few years. 12-3 Fatty acid-rich lipid emulsions have been developed for parenteral application in clinical situations, designed to shift the arachidonic acid (AA): eicosapentaenoic acid (EPA) value toward predominance of the latter lipid-mediator precursor. Many of the...
متن کاملIncorporated Fish Oil Fatty Acids Prevent Action Potential Shortening Induced by Circulating Fish Oil Fatty Acids
Increased consumption of fatty fish, rich in omega-3-polyunsaturated fatty acids (ω3-PUFAs) reduces the severity and number of arrhythmias. Long-term ω3-PUFA-intake modulates the activity of several cardiac ion channels leading to cardiac action potential shortening. Circulating ω3-PUFAs in the bloodstream and incorporated ω3-PUFAs in the cardiac membrane have a different mechanism to shorten t...
متن کاملTHE USE OF BREAST STIMULATION TO PREVENT POSTDATE PREGNANCY
Postdate pregnancy is estimated to occur in 3% to 12% of all gestations. Morbidity and mortality rates associated with this common obstetric problem are higher than those with term gestation. The incidence of fetal distress, birth injury, meconium aspiration, congenital malformations, macrosomia, and oligohydramnios is also greater in postdate pregnancies. We prospectively evaluated breast ...
متن کاملGene therapy approaches to prevent corneal graft rejection: where do we stand?
Cornea transplantation (penetrating keratoplasty) is the most frequently performed transplant procedure in humans. Despite advances in microsurgery and immunosuppressive treatment protocols, a significant number of corneal grafts still undergo immune-mediated allograft rejection. Topical treatment with corticosteroids is currently the gold standard and while this treatment is effective in many ...
متن کاملDaclizumab to prevent rejection after cardiac transplantation.
BACKGROUND Daclizumab, a humanized monoclonal antibody against the interleukin-2 receptor, reduced the risk of rejection without increasing the risk of infection among renal-transplant recipients and, in a single-center trial, among cardiac-transplant recipients. We conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transplant patients. METHODS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the Nutrition Society
سال: 1998
ISSN: 0029-6651,1475-2719
DOI: 10.1079/pns19980084